A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting

Lung-targeting drugs are thought to be potential therapies of refractory lung diseases by maximizing local drug concentrations in the lung to avoid systemic circulation. However, a major limitation in developing lung-targeted drugs is the acquirement of lung-specific ligands. Pulmonary surfactant pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shan-Mei, He, Xian, Li, Nan, Yu, Feng, Hu, Yang, Wang, Liu-Sheng, Zhang, Peng, Du, Yu-Kui, Du, Shan-Shan, Yin, Zhao-Fang, Wei, Ya-Ru, Mulet, Xavier, Coia, Greg, Weng, Dong, He, Jian-Hua, Wu, Min, Li, Hui-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403696/
https://www.ncbi.nlm.nih.gov/pubmed/25926731
http://dx.doi.org/10.2147/IJN.S77268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403696/
https://www.ncbi.nlm.nih.gov/pubmed/25926731
http://dx.doi.org/10.2147/IJN.S77268

Ejemplares similares